Skip to content Skip to footer
Subscribe Now

INSIGHTS+

PharmaShots' Key Highlights of Third Quarter 2023
PharmaShots’ Key Highlights of Third Quarter 2023
Shots: Third quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. Starting with the latest acquisitions, Biogen acquired Reata Pharmaceuticals for ~$7.3B and Danaher acquired Abcam for ~$5.7B The third quarter of the year also showcases multiple clinical trial results which include Janssen reported P-IIb…
October 2, 2023
Insights+: EMA Marketing Authorization of New Drugs in August 2023
Insights+: EMA Marketing Authorization of New Drugs in August 2023
Shots: The EMA approved 5 New Chemical Entity (NCE) and 6 Biologic Drugs in August 2023, leading to treatments for patients and advances in the healthcare industry In August 2023, the major highlight drugs were Aquipta (atogepant) approved for the preventive treatment of migraine in adults & Opdivo (nivolumab) as an adjuvant treatment for completely…
September 28, 2023
Know Your Investor: F-Prime Capital Partners
Know Your Investor: F-Prime Capital Partners
Shots: PharmaShots' tertiary report on the Know Your Investor Section features F-Prime Capital Partners. Know Your Investor is an earnest effort from PharmaShots to acquaint our readers with leading Investors and venture capital firms in the healthcare industry Founded in 1969, F-Prime Capital Partners is a subsidiary of Fidelity Investments and primarily invests in healthcare…
September 28, 2023
Top Performing Drug – Ozempic (September Edition)
Top Performing Drug – Ozempic (September Edition)
Shots:  PharmaShots’ next episode on the top-performing drug of the month, based on 2021 revenue, focuses on Ozempic, a drug developed and marketed by Novo Nordisk    Ozempic (semaglutide) is a human GLP-1 receptor agonist (or GLP-1 analog). It, when taken along with diet and exercise, is proven to improve blood sugar in adults with type 2…
September 27, 2023
Insights+: The US FDA New Drug Approvals in August 2023
Insights+: The US FDA New Drug Approvals in August 2023
Shots: The US FDA approved 10 NDAs and 3 BLA in August 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 89 novel products in 2023 In August 2023, the major highlights drugs were Zurzuvae (zuranolone) approval for women with postpartum depression and Veopoz (pozelimab-bbfg) for children…
September 20, 2023
New Drug Designations - August 2023
New Drug Designations – August 2023
Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, the EU, Japan, and China. This month’s report includes 8 biological drugs, 13 small molecules, 4 cell and gene therapies, 3 diagnostic tests and 5 devices  Genprex’ Reqorsa, focused on the treatment of SCLC, is the drug to receive ODD…
September 18, 2023
Disease of the Month- Mesothelioma
Disease of the Month- Mesothelioma
Shots:  To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research   Continuing the series for the disease of the month, PharmaShots brings a condensed report on Mesothelioma, a type of cancer that affects the lining of…
September 14, 2023
Insights+ Key Biosimilars Events of August 2023
Insights+ Key Biosimilars Events of August 2023
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients During the month of August, Sandoz’ Tyruko (biosimilar, natalizumab) received the US FDA’s…
September 6, 2023
Know Your Investor: RA Capital Management LLC
Shots: PharmaShots’ second dose of the Know Your Investor series focuses on RA Capital Management LLC. Know Your Investor is an earnest effort from PharmaShots to acquaint our readers with leading Investors and venture capital firms in the healthcare industry Founded in 2002, RA Capital forged ahead to become a key investor in life science…
August 31, 2023
Insights+: EMA Marketing Authorization of New Drugs in July 2023
Insights+: EMA Marketing Authorization of New Drugs in July 2023
Shots: The EMA approved 9 New Chemical Entity (NCE) and 5 Biologic Drugs in July 2023, leading to treatments for patients and advances in the healthcare industry In July 2023, the major highlights drugs were Soliris approval for refractory generalised myasthenia gravis and Trodelvy for pre-treated HR+/HER2- metastatic breast cancer PharmaShots has compiled a list…
August 24, 2023
Load more